CTRI/2011/08/001975已完成2 期
A Phase II Study of Dasatinib Therapy in Children and Adolescents with Newly Diagnosed Chronic Phase CML or with Ph+ Leukemias Resistant or Intolerant to Imatinib
BristolMyers Squibb India Pvt Ltd0 个研究点目标入组 110 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Inclusion criterias:
- •1)Age 2 to 18 years.
- •2)Lansky or Karnofsky scale >50.
- •3)Life expectancy more than 12 weeks.
- •4)Any toxicity from recent therapies recovered to baseline or grade 1.
- •5)Adequate hepatic and renal function.
排除标准
- •Prior therapy with dasatinib
- •Eligible for potentially curative therapy including hematopoietic stem-cell transplantation
- •Symptomatic central nervous system disease
- •Isolated extramedullary disease
- •Medical condition significantly impairing ability of patient to receive dasatinib
- •T315I mutation in BCR-AB
研究者
相似试验
招募中
2 期
A Phase II Study of Dasatinib Therapy in Children and Adolescents with Ph+ Leukemiawith Resistance or Intolerance to ImatinibRBR-5hzmjxBristol-Myers Squibb
进行中（未招募）
1 期
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to ImatinibChildren and Adolescents with Newly Diagnosed Chronic Phase CML or with Ph+ Leukemias Resistant to or Intolerant to ImatinibMedDRA version: 21.0Level: PTClassification code 10034877Term: Philadelphia chromosome positiveSystem Organ Class: 10022891 - InvestigationsMedDRA version: 20.1Level: LLTClassification code 10024329Term: LeukemiaSystem Organ Class: 100000004864EUCTR2008-002260-33-DEBristol Myers Squibb International Corporation145
已完成
2 期
A Phase II Study of Dasatinib Therapy in Children and Adolescents with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia or with Ph+ Leukaemias Resistant or Intolerant to ImatinibLeukemias10024324NL-OMON47600Bristol-Myers Squibb6
进行中（未招募）
1 期
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to ImatinibEUCTR2008-002260-33-GBBristol Myers Squibb International Corporation120
进行中（未招募）
1 期
A Phase II Study of Dasatinib in Children and Adolescents with Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib.Children and Adolescents with Newly Diagnosed Chronic Phase CML or with Ph+ Leukemias Resistant to or Intolerant to ImatinibMedDRA version: 21.0Level: PTClassification code: 10034877Term: Philadelphia chromosome positive Class: 100000004848MedDRA version: 20.1Level: LLTClassification code: 10024329Term: Leukemia Class: 10029104CTIS2024-510784-36-00Bristol Myers Squibb International Corporation149